Semaglutide for Weight Loss: Clinics, Cost & What to Know

Semaglutide is a GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate appetite, slow gastric emptying, and improve insulin sensitivity. In the FDA reference file, semaglutide appears in multiple branded products, including Wegovy for chronic weight management and Ozempic for type 2 diabetes.

For weight loss, the key branded product is Wegovy, which received FDA approval in June 2021 for chronic weight management in adults who meet the labeled BMI criteria. Ozempic is FDA-approved for type 2 diabetes, not weight loss, even though it is commonly discussed in that context.

The STEP 1 trial, 2021 reported average body-weight loss of 14.9% over 68 weeks for Wegovy versus 2.4% with placebo. The FDA reference also notes STEP 2 and STEP 3, which showed meaningful weight-loss results in patients with type 2 diabetes and in intensive behavioral-therapy settings.

Per the FDA label, Wegovy starts at 0.25 mg weekly and escalates monthly until a 2.4 mg weekly maintenance dose. Ozempic starts at 0.25 mg weekly, then typically increases to 0.5 mg, with a labeled maximum of 2 mg weekly.

Brand-name semaglutide pricing depends on which product is prescribed. The FDA reference lists Wegovy at roughly $1,300 to $1,400 per month retail and Ozempic at roughly $900 to $1,000 per month retail.

Prices vary by pharmacy and location, so these numbers are best used as planning ranges rather than guarantees.

Manufacturer savings programs may be available for some branded semaglutide prescriptions, but eligibility and availability vary.

Prices vary by pharmacy, location, and clinic structure.

Semaglutide and tirzepatide are both weekly incretin-based medications, but tirzepatide acts on both GIP and GLP-1 receptors while semaglutide targets GLP-1 alone.

The reference file notes stronger weight-loss results for tirzepatide in SURMOUNT-1, but there is no direct head-to-head trial comparing Zepbound 15 mg with Wegovy 2.4 mg. That means cleaner clinic conversations usually focus on goals, side effects, access, and coverage rather than blanket claims about which drug is better.